HBsAg-Negative, Anti-HBc–Negative Patients Still Have a Risk of Hepatitis B Virus–Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma.
- Author:
Hyunsung PARK
1
;
Do Young KIM
;
Soo Jeong KIM
;
Haerim CHUNG
;
Hyunsoo CHO
;
Ji Eun JANG
;
June Won CHEONG
;
Yoo Hong MIN
;
Jae Woo SONG
;
Jin Seok KIM
Author Information
- Publication Type:Original Article
- Keywords: Hepatitis B core antibody; HBV-related hepatitis; Stem cell transplantation; Lymphoma; Multiple myeloma
- MeSH: Diagnosis; Drug Therapy; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B*; Hepatitis*; Humans; Lymphoma*; Multiple Myeloma*; Retrospective Studies; Stem Cell Transplantation*; Stem Cells*
- From:Cancer Research and Treatment 2018;50(4):1121-1129
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Although hepatitis B surface antigen (HBsAg)–negative, hepatitis B core antibody (anti-HBc)–negative patients are not considered to be at risk for hepatitis B virus (HBV)–related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc–negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma. MATERIALS AND METHODS: We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc–negative and 110 anti-HBc–positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma. RESULTS: Three patients (two anti-HBc–negative MMs and one anti-HBc–positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients (16.7% with MM and 5.4% with lymphoma) who were HBsAg–negative and anti-HBc–positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT. CONCLUSION: Our data suggest that HBsAg-negative, anti-HBc–negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis.
